474 related articles for article (PubMed ID: 16450901)
1. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
Afify A; Zhou H; Howell L; Paulino AF
Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
[TBL] [Abstract][Full Text] [Related]
2. GLUT1 antibody staining in thin-layer specimens of benign and malignant body cavity effusions.
Mensch LS; Weller L; Simmons-Arnold L; Gibson PC; Leiman G; Beatty B
Acta Cytol; 2002; 46(5):813-8. PubMed ID: 12365212
[TBL] [Abstract][Full Text] [Related]
3. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.
Afify AM; al-Khafaji BM
Acta Cytol; 2002; 46(4):675-8. PubMed ID: 12146029
[TBL] [Abstract][Full Text] [Related]
5. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
Barberis MC; Faleri M; Veronese S; Casadio C; Viale G
Acta Cytol; 1997; 41(6):1757-61. PubMed ID: 9390137
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids.
Afify A; Pang L; Howell L
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):446-50. PubMed ID: 18091389
[TBL] [Abstract][Full Text] [Related]
7. Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions.
Grefte JM; de Wilde PC; Salet-van de Pol MR; Tomassen M; Raaymakers-van Geloof WL; Bulten J
Acta Cytol; 2008; 52(1):35-44. PubMed ID: 18323273
[TBL] [Abstract][Full Text] [Related]
8. Identification of malignant cells in serous effusions using a panel of monoclonal antibodies Ber-EP4, MCA-b-12 and EMA.
Stoop JA; Hendriks JG; Berends D
Cytopathology; 1992; 3(5):297-302. PubMed ID: 1288655
[TBL] [Abstract][Full Text] [Related]
9. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
[TBL] [Abstract][Full Text] [Related]
10. Quality control of immunocytochemical staining of effusions using a standardized method of cell processing.
Kuenen-Boumeester V; van Loenen P; de Bruijn EM; Henzen-Logmans SC
Acta Cytol; 1996; 40(3):475-9. PubMed ID: 8669182
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions.
Zimmerman RL; Fogt F; Goonewardene S
Cancer; 2000 Aug; 90(4):230-4. PubMed ID: 10966563
[TBL] [Abstract][Full Text] [Related]
13. Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3.
Martin SE; Moshiri S; Thor A; Vilasi V; Chu EW; Schlom J
Am J Clin Pathol; 1986 Jul; 86(1):10-8. PubMed ID: 3524191
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4.
De Angelis M; Buley ID; Heryet A; Gray W
Cytopathology; 1992; 3(2):111-7. PubMed ID: 1617160
[TBL] [Abstract][Full Text] [Related]
15. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases.
Diaz-Arias AA; Loy TS; Bickel JT; Chapman RK
Diagn Cytopathol; 1993 Oct; 9(5):516-21. PubMed ID: 8287759
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.
Maguire B; Whitaker D; Carrello S; Spagnolo D
Diagn Cytopathol; 1994; 10(2):130-4. PubMed ID: 8187591
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
[TBL] [Abstract][Full Text] [Related]
20. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
